HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells
Primary liver cancer is the fifth leading death of cancers in men, and hepatocellular carcinoma (HCC) accounts for approximately 90% of all primary liver cancer cases. Sorafenib is a first-line drug for advanced-stage HCC patients. Sorafenib is a multi-target kinase inhibitor that blocks tumor cell...
Main Authors: | Fat-Moon Suk, Chien-Ying Wu, Wan-Chun Chiu, Chia-Ying Chien, Tzu-Lang Chen, Yi-Jen Liao |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/27/22/8015 |
Similar Items
-
β-HB treatment reverses sorafenib resistance by shifting glycolysis–lactate metabolism in HCC
by: Fat-Moon Suk, et al.
Published: (2023-10-01) -
Secretory NPC2 Protein-Mediated Free Cholesterol Levels Were Correlated with the Sorafenib Response in Hepatocellular Carcinoma
by: Fat-Moon Suk, et al.
Published: (2021-08-01) -
Long-term di-(2-ethylhexyl) phthalate exposure reduces sorafenib treatment efficacy by enhancing mesenchymal transition in hepatocellular carcinoma
by: Ming-Syuan Shih, et al.
Published: (2024-03-01) -
Sorafenib-induced acute pancreatitis
by: Han-En Wang, et al.
Published: (2014-01-01) -
Loss of HMGCS2 Enhances Lipogenesis and Attenuates the Protective Effect of the Ketogenic Diet in Liver Cancer
by: Yuan-Hsi Wang, et al.
Published: (2020-07-01)